Solid Biosciences LLC (SLDB) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-1.13x
Solid Biosciences LLC (SLDB) has a Cash Flow-to-Debt Ratio of -1.13x as of June 2026, meaning its operating cash flow of $-52.59 Million could theoretically repay -1% of its total liabilities ($46.51 Million) in one year. See Solid Biosciences LLC (SLDB) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-1.13x
Operating CF / Total Liabilities
Operating Cash Flow
$-52.59 Million
USD
Total Liabilities
$46.51 Million
USD
Data as of
Jun 2026
Most recent filing
Solid Biosciences LLC Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Solid Biosciences LLC across 11 annual periods. For the full cash flow conversion analysis, see SLDB cash flow metrics.
Annual Cash Flow-to-Debt Ratio for Solid Biosciences LLC (2015–2025)
Year-by-year debt coverage analysis for Solid Biosciences LLC.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.98x | $-156.29 Million | $52.53 Million | ▼ -53.0% |
| 2024 | -1.95x | $-100.01 Million | $51.42 Million | ▲ +20.6% |
| 2023 | -2.45x | $-94.18 Million | $38.46 Million | ▼ -21.4% |
| 2022 | -2.02x | $-97.98 Million | $48.59 Million | ▲ +37.3% |
| 2021 | -3.22x | $-77.76 Million | $24.17 Million | ▼ -122.2% |
| 2020 | -1.45x | $-56.60 Million | $39.08 Million | ▲ +63.4% |
| 2019 | -3.96x | $-92.71 Million | $23.42 Million | ▲ +18.7% |
| 2018 | -4.87x | $-70.20 Million | $14.41 Million | ▼ -1426.1% |
| 2017 | -0.32x | $-43.22 Million | $135.45 Million | ▼ -24.5% |
| 2016 | -0.26x | $-20.12 Million | $78.52 Million | ▼ -360.9% |
| 2015 | -0.06x | $-4.20 Million | $75.62 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.